The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.
Last year, the firm saw 21 percent growth in reproductive health, 56 percent growth in oncology, and 49 percent growth in infectious disease testing.
A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
The firm said that the new instrument, which prepares slides for cytology and aliquot samples for molecular testing, offers workflow benefits to clinical labs.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
The German firm said that researchers can now run its GynTect cervical cancer assay on Roche Diagnostics' Cobas z 480 analyzer.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The firms said that HuaSin obtained exclusive rights to develop a fully automated HPV genotyping assay platform that uses Genomica’s technology.
In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.